---
title: "CagriSema"
canonical_url: https://peptidelibrary.app/library/cagrisema
description: "Fixed-dose combination of cagrilintide plus semaglutide in Novo Nordisk Phase 3 REDEFINE programs. Not FDA-approved as of 2026."
updated: 2026-11-07
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# CagriSema

CagriSema (also called Cagrilintide + semaglutide or NN9838 + semaglutide) is a research peptide in the GLP-1 Agonist class. CagriSema is a fixed-ratio co-formulation of cagrilintide, a long-acting amylin receptor agonist, and semaglutide, a GLP-1 receptor agonist, delivered as a single weekly injection.

Fixed-dose combination of cagrilintide plus semaglutide in Novo Nordisk Phase 3 REDEFINE programs. Not FDA-approved as of 2026.

Also known as: Cagrilintide + semaglutide, NN9838 + semaglutide.

Categories: Fat Loss, GLP-1/Metabolic.

## Classification

- Type: Investigational amylin + GLP-1 combination
- Mechanism class: GLP-1 Agonist
- Development stage: In clinical development
- Regulatory class: Investigational, not FDA-approved

## Mechanism

CagriSema is a fixed-ratio co-formulation of cagrilintide, a long-acting amylin receptor agonist, and semaglutide, a GLP-1 receptor agonist, delivered as a single weekly injection. The two act on separate satiety pathways: amylin signalling operates through amylin and calcitonin receptor complexes in the area postrema, while GLP-1 acts on its own receptors in the hypothalamus and brainstem. Because the pathways converge on food intake without sharing a receptor, the combination is intended to produce greater appetite suppression than either alone, and it is being studied to determine whether that translates into additive weight reduction.

Targets: GLP-1 receptor, Amylin receptor.

Origin: Investigational combination of two peptides.

## Properties

- Studied routes: Subcutaneous

## Evidence

- Evidence level: Clinical Trial Evidence
- Highest documented: Controlled human trials
- Human trials: 4
- Controlled human trials: 4
- Preclinical sources: 0
- Latest source: 2026

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2025. 2025. Controlled human trial. Population: Adults with obesity, or overweight with a related condition, without diabetes (n=3,417). Mean body-weight change -20.4% with CagriSema against -3.0% with placebo; gastrointestinal events in 79.6% against 39.9% [Source](https://pubmed.ncbi.nlm.nih.gov/40544433/)
2. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. N Engl J Med. 2025. 2025. Controlled human trial. Population: Adults with BMI ≥27, HbA1c 7–10% and type 2 diabetes (n=1,206). Mean body-weight change -13.7% against -3.4% with placebo; HbA1c ≤6.5% reached by 73.5% against 15.9% [Source](https://pubmed.ncbi.nlm.nih.gov/40544432/)
3. Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1). Lancet Diabetes Endocrinol. 2026. 2026. Controlled human trial. Population: Adults with type 2 diabetes on diet and exercise (n=189) [Source](https://pubmed.ncbi.nlm.nih.gov/42251860/)
4. Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study. Lancet Diabetes Endocrinol. 2026. 2026. Controlled human trial. Population: Adults with type 2 diabetes on metformin with or without an SGLT2 inhibitor, BMI ≥25 (n=2,713) [Source](https://pubmed.ncbi.nlm.nih.gov/42251859/)

## Safety

Side effects: Nausea; Constipation; GI class effects.

Risks: Not approved; WADA S0 for the unapproved combo.

Human safety basis: Clinical trial reports

Key limitations: Not approved by the FDA for any use..

## Regulatory status

CagriSema has been studied under an Investigational New Drug application. It is not approved for marketing.

- FDA status: Investigational New Drug (IND)
- WADA status: Banned in Sport
- Availability: Research-Only

## Frequently asked questions

### How does CagriSema work?

CagriSema is a fixed-ratio co-formulation of cagrilintide, a long-acting amylin receptor agonist, and semaglutide, a GLP-1 receptor agonist, delivered as a single weekly injection. The two act on separate satiety pathways: amylin signalling operates through amylin and calcitonin receptor complexes in the area postrema, while GLP-1 acts on its own receptors in the hypothalamus and brainstem.

### Is CagriSema FDA approved?

No. CagriSema is investigational: it is in clinical development and has not been approved by the FDA for any indication. Investigational status means trials are ongoing or complete but regulatory review has not resulted in approval, and efficacy and safety are still being established.

### Is CagriSema banned in sport?

CagriSema is recorded here as prohibited in sport. Athletes subject to anti-doping rules should check the current WADA Prohibited List directly, since it is revised annually and classifications change.

### What peptides are similar to CagriSema?

Compounds most often compared with CagriSema include Cagrilintide, Pramlintide, Petrelintide and Amycretin. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [WADA Prohibited List 2026](https://www.wada-ama.org/en/prohibited-list)
- [CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1 — Hypertension, 2026](https://pubmed.ncbi.nlm.nih.gov/41328546/)
- [Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study — Lancet Diabetes Endocrinol, 2026](https://pubmed.ncbi.nlm.nih.gov/42251860/)
- [Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study — Lancet Diabetes Endocrinol, 2026](https://pubmed.ncbi.nlm.nih.gov/42251859/)
- [Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes — N Engl J Med, 2025](https://pubmed.ncbi.nlm.nih.gov/40544432/)
- [Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis — BMJ, 2026](https://pubmed.ncbi.nlm.nih.gov/42419792/)

Note: Dose figures are left out of this Markdown version. See the cited sources.
